![Altimmune Inc](/common/images/company/N_ALT.png)
Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the tre... Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH (non-alcoholic steatohepatitis). In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B virus (HBV). Show more
Lost Money on Altimmune, Inc.(ALT)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm PR Newswire NEW YORK, July 3, 2024 NEW YORK, July 3, 2024 /PRNewswire/ -- The Gross Law...
GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Companyās management team will...
Lost Money on Altimmune, Inc.(ALT)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm PR Newswire NEW YORK, June 28, 2024 NEW YORK, June 28, 2024 /PRNewswire/ -- The Gross Law...
GAITHERSBURG, Md., June 26, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc.Ā (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Richard Eisenstadt, the Companyās Chief...
Shareholders that lost money on Altimmune, Inc.(ALT) should contact The Gross Law Firm about pending Class Action - ALT PR Newswire NEW YORK, June 25, 2024 NEW YORK, June 25, 2024 /PRNewswire/...
GAITHERSBURG, Md., June 23, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc.Ā (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today presented data from the 48-week Phase 2 MOMENTUM clinical...
GAITHERSBURG, Md., June 22, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc.Ā (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today presented data on the effect of pemvidutide, its...
GAITHERSBURG, Md., June 20, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Companyās management team will...
Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before July 5, 2024 to Discuss Your Rights - ALT PR Newswire NEW YORK, June 20, 2024 NEW YORK, June 20...
GAITHERSBURG, Md., June 18, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced oral presentations on pemvidutide, an...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.55 | -19.5707070707 | 7.92 | 8.26 | 6.0905 | 2922326 | 6.9542739 | CS |
4 | -0.74 | -10.4078762307 | 7.11 | 8.26 | 6.06 | 3805240 | 6.98913275 | CS |
12 | 0.02 | 0.314960629921 | 6.35 | 9.5 | 5.64 | 3588604 | 7.07640119 | CS |
26 | -3.59 | -36.0441767068 | 9.96 | 14.84 | 5.64 | 4153041 | 8.78053547 | CS |
52 | 3.19 | 100.314465409 | 3.18 | 14.84 | 2.09 | 5029658 | 7.49945075 | CS |
156 | -2.89 | -31.2095032397 | 9.26 | 23.49 | 2.09 | 2685279 | 8.46140304 | CS |
260 | 4.05 | 174.568965517 | 2.32 | 35.1 | 1.45 | 2291487 | 9.88876592 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.